Polyvalent derivatives of emoxypine
AssigneeALSaTECH, Inc.
InventorsClaude NICOLAU, Jean-Marie LEHN, Renald THINARD, Youssef ATOINI
Life of this patent
Estimating the term…
Abstract
Use of polyvalent emoxypine derivatives or related compounds in the treatment or prevention of, inter alia, Parkinson's Disease are described.
Claims18
A method for treating or preventing a synucleinopathy, comprising administering an effective amount of a polyvalent derivative of emoxypine.
The method of any of the preceding claims, wherein the synucleinopathy is a condition characterized by Lewy bodies.
The method of any of the preceding claims, wherein the synucleinopathy is selected from Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
The method of any of the preceding claims, wherein the disaggregation of α-synuclein comprises about a 20%, or about a 30%, or about a 40%, or about a 50%, or about a 60%, or about a 70%, or about a 80%, or about a 90%, or about a 95%, or about a 100% reduction in α-synuclein aggregation relative to an untreated subject.
The method of any of the preceding claims, wherein the method does not substantially dissolve aggregates of beta-amyloid.
Use of a compound of Formula I in the treatment of a synucleinopathy,
- wherein:
- X is —NH—C(═O)— or —CH(═N)—;
- each R5, R6, or R7 is independently halo, nitro, OH, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, (C2-C8) heterocyclo, aryl, or heteroaryl;
- each t is independently 0, 1, 2, 3, 4, or 5;
- each k is independently 0, 1, 2, 3, 4, 5, or 6;
- wherein the use comprises disaggregation of α-synuclein.
Use of a compound of Formula II in the treatment of a synucleinopathy,
- wherein:
- X is —NH—C(═O)— or —CH(═N)—;
- each R1, R2, R3, or R4 is independently halo, nitro, OH, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, (C2-C8) heterocyclo, aryl, or heteroaryl;
- n is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15;
- each t is independently 0, 1, 2, 3, 4, or 5;
- each k is independently 0, 1, 2, 3, 4, 5, or 6;
- wherein the use comprises disaggregation of α-synuclein.
A method for the treatment of Parkinson's disease, comprising administering an effective amount of a polyvalent derivative of emoxypine of Formula I:
- wherein:
- X is —NH—C(═O)— or —CH(═N)—;
- each R5, R6, or R7 is independently halo, nitro, OH, (C1-C6)alkyl, (C1-C6)alkoxy, halo(C1-C6)alkyl, (C2-C6)alkenyl, (C3-C8)cycloalkyl, (C2-C8) heterocyclo, aryl, or heteroaryl;
- each t is independently 0, 1, 2, 3, 4, or 5;
- each k is independently 0, 1, 2, 3, 4, 5, or 6.
Dependencies are inferred from the claim text.